2,851
edits
Bioavailability: Difference between revisions
→Measuring Bioavailability
| Line 18: | Line 18: | ||
Bioavailability is often assessed through specific pharmacokinetic studies, which evaluate the concentration of a drug in plasma over time. The two key metrics used are absolute and relative bioavailability. | Bioavailability is often assessed through specific pharmacokinetic studies, which evaluate the concentration of a drug in plasma over time. The two key metrics used are absolute and relative bioavailability. | ||
=== | === Absolute Bioavailability === | ||
This measures the bioavailability of a drug compared to its intravenous administration. The formula for calculating absolute bioavailability (F) is: | This measures the bioavailability of a drug compared to its intravenous administration. The formula for calculating absolute bioavailability (F) is: | ||
| Line 25: | Line 25: | ||
where AUC is the [[Area Under the Curve (AUC)|area under the plasma concentration-time curve]] for oral (AUC<sub>oral</sub>) and intravenous (AUC<sub>IV</sub>) administration, and Dose refers to the dose administered via each route. | where AUC is the [[Area Under the Curve (AUC)|area under the plasma concentration-time curve]] for oral (AUC<sub>oral</sub>) and intravenous (AUC<sub>IV</sub>) administration, and Dose refers to the dose administered via each route. | ||
=== | === Relative Bioavailability === | ||
Relative bioavailability compares the bioavailability of a drug in different formulations, typically against a standard or reference formulation. The formula is: | Relative bioavailability compares the bioavailability of a drug in different formulations, typically against a standard or reference formulation. The formula is: | ||